Vol 1, No 3 (2010)
Case report
Published online: 2010-07-27
Tyrosine kinase inhibitors-induced myelosuppression - case report
Hematologia 2010;1(3):249-253.
Abstract
This paper presents a patient with chronic myeloid leukemia (CML) in chronic phase and
profound myelosuppression induced by tyrosine kinase inhibitors (TKI), included imatinib,
dasatinib and nilotinib. Therapy with each of TKI was complicated by severe cytopenia, which
resulted in interruptions and daily dose reduction of the drugs. Finally, myelosuppression and
reduced dense-dosage of each TKI resulted in CML treatment failure. This case illustrates the
therapeutic difficulties related to TKI-induced myelosuppresion in the chronic phase of CML.
Hematologia 2010; 1, 3: 249-253
Hematologia 2010; 1, 3: 249-253
Keywords: chronic myeloid leukemiaimatinibdasatinibnilotinibmyelosuppression